Insights from ESMO24 Day 2

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.

ESMO shared some insights from the conference on social media.

Benefits of BRAF and MEK inhibitors

Benefits of BRAF and MEK inhibitors confirmed in BRAF V600E-mutant NSCLC. Longer duration of efficacy with encorafenib–binimetinib in update from PHAROS trial and positive data in a second trial.

Leveraging team science to exploit the tumour’s ‘Achilles heel’

Leveraging team science to exploit the tumour’s ‘Achilles heel’ with PARP inhibition has been a journey of discovery and perseverance. Global efforts drive research into mechanisms, predictors and possible resistance prevention.

Neoadjuvant immunotherapy combinations in stage III melanoma

Unprecedented, lasting survival benefit reported with neoadjuvant immunotherapy combinations in stage III melanoma. Neoadjuvant nivolumab and ipilimumab also showed superior survival vs adjuvant nivolumab in the NADINA trial.

Taxane- and anthracycline-sparing regimens show promise in high-risk, Early Breast Cancer

pCR rates of 79% with datopotamab, deruxtecan and durvalumab in patients with immune-positive signatures.

Umberto Malapelle providing insights in an editorial

Presented studies add to knowledge about the role of Liquid Biopsy, particularly ctDNA, in early-stage NSCLC. Umberto Malapelle provides insights in an editorial.

Women representation in oncology is still low

Women representation in oncology is still low in society boards, congresses, as lead authors in publications, though progress has been made. Listen to Helena Linardou 16 Sept at 14:45, Policy and preventive strategies Mini oral session showing exact worrying figures.

Insights into the driver landscape of healthy and cancerous pancreatic tissue

KRAS and TP53 may have unique malignant transformative potential in Pancreatic Cancer development. Insights into the driver landscape of healthy and cancerous pancreatic tissue show improved outcomes prediction.

Breastfeeding after Breast Cancer is feasible and safe

New data suggesting no signals that breastfeeding compromises the outcome of Breast Cancer will be valuable in guiding patient-centred decisions.

For more updates on ESMO24, visit oncodaily.com